Immune checkpoint inhibitors in mCRPC - rationales, challenges and perspectives
- PMID: 31646092
- PMCID: PMC6791446
- DOI: 10.1080/2162402X.2019.1644109
Immune checkpoint inhibitors in mCRPC - rationales, challenges and perspectives
Abstract
The advancement of immune-therapeutics in cancer treatment has proven to be promising in various malignant diseases. However, in castration resistant prostate cancer (mCRPC) major Phase III trials have been unexpectedly disappointing. To contribute to a broader understanding of the role and use of immune-therapeutics in mCRPC, we conducted a systematic review. We searched the websites ClinicalTrials.gov, PubMed and ASCO Meeting Library for clinical trials employing immune checkpoint inhibitors in mCRPC. This article not only describes the rationale of individual trials, but it also summarizes the current status of the field and sheds light on strategies for future success.
Keywords: T lymphocytes; checkpoint inhibitors; immunotherapy; mCRPC; vaccines.
© 2019 The Author(s). Published with license by Taylor & Francis Group, LLC.
References
-
- American Cancer Society About prostate cancer. 2016. [accessed 2018 October11]. https://www.cancer.org/cancer/prostate-cancer.html.
-
- Prostate Cancer Foundation Prostate cancer treatment. 2018. [accessed 2018 October11]. https://www.pcf.org/about-prostate-cancer/prostate-cancer-treatment/.
-
- National Cancer Institute Prostate cancer treatment. 2018. [accessed 2018 October11]. https://www.cancer.gov/types/prostate/hp/prostate-treatment-pdq.
-
- Cancer.Net Prostate cancer guide. 2018. [accessed 2018 October11]. https://www.cancer.net/cancer-types/prostate-cancer/types-treatment.
-
- Institute, N.C Immune checkpoint inhibitor. [accessed 2019 May]. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/immune....
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources